- Bank of America Merrill Lynch names Sarepta (SRPT -0.2%) as the top small- to mid-cap pick in biotech for H2 and sees several near-term catalysts for the company.
- The firm cites upside potential from Sarepta's LGMD gene therapy pipeline, which isn't priced into the current valuation.
- Analyst Tazeen Ahmad says LGMD2E clinical data is encouraging and notes that the treatment doesn't have competition.
- Ahmad also calls Sarepta a front-runner in DMD with plans to initiate a pivotal commercial supply study by the end of the year.
- Pfizer will present data for its dystrophin DMD gene therapy at the end of the month. Ahmad writes that in the worst-case scenario, Pfizer would look competitive with Sarepta, an outcome that wouldn't change the analyst's estimates.
- SRPT has an Outperform average Sell Side rating.
BofAML names Sarepta as top pick
Recommended For You
More Trending News
About SRPT Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
SRPT | - | - |
Sarepta Therapeutics, Inc. |